Non-Coding RNA (May 2024)

Dysregulation of a Subset of Circulating and Vesicle-Associated miRNA in Pancreatic Cancer

  • Giulia Girolimetti,
  • Iulia Andreea Pelisenco,
  • Leonardo Henry Eusebi,
  • Claudio Ricci,
  • Beatrice Cavina,
  • Ivana Kurelac,
  • Tiziano Verri,
  • Matteo Calcagnile,
  • Pietro Alifano,
  • Alessandro Salvi,
  • Cecilia Bucci,
  • Flora Guerra

DOI
https://doi.org/10.3390/ncrna10030029
Journal volume & issue
Vol. 10, no. 3
p. 29

Abstract

Read online

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive neoplasia, characterized by early metastasis, low diagnostic rates at early stages, resistance to drugs, and poor prognosis. There is an urgent need to better characterize this disease in order to identify efficient diagnostic/prognostic biomarkers. Since microRNAs (miRNAs) contribute to oncogenesis and metastasis formation in PDAC, they are considered potential candidates for fulfilling this task. In this work, the levels of two miRNA subsets (involved in chemoresistance or with oncogenic/tumor suppressing functions) were investigated in a panel of PDAC cell lines and liquid biopsies of a small cohort of patients. We used RT-qPCR and droplet digital PCR (ddPCR) to measure the amounts of cellular- and vesicle-associated, and circulating miRNAs. We found that both PDAC cell lines, also after gemcitabine treatment, and patients showed low amounts of cellular-and vesicle-associated miR-155-5p, compared to controls. Interestingly, we did not find any differences when we analyzed circulating miR-155-5p. Furthermore, vesicle-related miR-27a-3p increased in cancer patients compared to the controls, while circulating let-7a-5p, miR-221-3p, miR-23b-3p and miR-193a-3p presented as dysregulated in patients compared to healthy individuals. Our results highlight the potential clinical significance of these analyzed miRNAs as non-invasive diagnostic molecular tools to characterize PDAC.

Keywords